Merck (Whitehouse Station, NJ) expects that emerging markets will account for more than 25% of its global pharmaceutical and vaccine revenue in 2013, based on the implementation of the company's emerging markets strategy. To accomplish this, Merck intends to launch new products, optimize its in-line portfolio of medicines, vaccines, follow-on biologics, and consumer care products, and fully leverage the market for branded generics with the company's portfolio of mature brands and targeted business development in these emerging markets.
The next emerging market Merck is looking to for expansion is South Africa.
MSD (as Merck is known outside the US and Canada) has formed a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute several established MSD products in South Africa.
The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough. Financial details of the collaboration were not disclosed.